TP53 and neoplasm: Among the variants identified in the MLH1-deficient tumor area, the c.670G>T (VAF 76.8%) pathogenic mutation in the TP53 gene introduces a premature stop codon, resulting in a truncated protein that disrupts the DNA damage response, thereby acting as a tumor driver.